CYTOSORBENTS CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CYTOSORBENTS CORPORATION (CTSO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.65 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.65, a 36.89% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.03, a 8.42% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.95, a 64.15% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.65, a 22.51% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.00, a 3.09% increase from fiscal 2024.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.97, a 71.72% decline from fiscal 2023.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $3.43, a 74.11% increase from fiscal 2022.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.97, a 77.56% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.65 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $0.65 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | $1.00 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $1.00 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $1.02 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $1.03 10-Q · filed 2025-05-14 | ||||
| 2024-12-31 | $0.97 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $0.96 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $0.95 10-Q · filed 2024-08-13 | ||||
| 2024-03-31 | $0.95 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $3.43 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $3.45 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $2.81 10-Q · filed 2023-08-01 | ||||
| 2023-03-31 | $2.65 10-Q · filed 2023-05-02 | ||||
| 2022-12-31 | $1.97 10-K · filed 2024-03-15 | $1.99 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $2.00 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $2.86 10-Q · filed 2022-08-02 | ||||
| 2022-03-31 | $3.42 10-Q · filed 2022-05-03 | ||||
| 2021-12-31 | $8.78 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $8.90 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $8.98 10-Q · filed 2021-08-03 | ||||
| 2021-03-31 | $8.66 10-Q · filed 2021-05-04 | ||||
| 2020-12-31 | $6.37 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | $6.18 10-Q · filed 2020-11-04 | ||||
| 2020-06-30 | $6.12 10-Q · filed 2020-08-04 | ||||
| 2020-03-31 | $6.03 10-Q · filed 2020-05-05 | ||||
| 2019-12-31 | $7.19 10-K · filed 2022-03-10 | ||||
| 2019-09-30 | $7.24 10-Q · filed 2019-11-05 | ||||
| 2019-06-30 | $7.09 10-Q · filed 2019-08-06 | ||||
| 2019-03-31 | $6.99 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | $8.01 10-K · filed 2021-03-09 | ||||
| 2018-09-30 | $7.98 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $8.48 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | $9.37 10-Q · filed 2018-05-08 | ||||
| 2017-12-31 | $5.46 10-K · filed 2020-03-05 | ||||
| 2017-09-30 | $5.45 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $5.45 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | $5.60 10-Q · filed 2017-05-08 | ||||
| 2016-12-31 | $4.68 10-K · filed 2019-03-07 | ||||
| 2016-09-30 | $4.68 10-Q · filed 2016-11-07 | ||||
| 2016-06-30 | $4.67 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $5.09 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | $7.88 10-K · filed 2018-03-08 | ||||
| 2015-09-30 | $7.90 10-Q · filed 2015-11-13 | ||||
| 2015-06-30 | $7.98 10-Q · filed 2015-08-13 | ||||
| 2015-03-31 | $4.40 10-Q · filed 2015-05-11 | ||||
| 2014-12-31 | $5.02 10-K · filed 2017-03-03 | ||||
| 2014-09-30 | $0.20 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | $0.20 10-Q · filed 2014-08-12 | ||||
| 2014-03-31 | $0.19 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $2.75 10-K · filed 2015-03-31 | $0.11 10-K · filed 2014-03-31 | |||
| 2013-09-30 | $0.11 10-Q · filed 2013-11-06 | ||||
| 2013-06-30 | $0.11 10-Q · filed 2013-08-14 | ||||
| 2013-03-31 | $0.11 10-Q · filed 2013-05-15 | ||||
| 2012-12-31 | $0.15 10-K · filed 2014-03-31 | ||||
| 2012-09-30 | $0.15 10-Q · filed 2012-11-21 | ||||
| 2012-06-30 | $0.15 10-Q · filed 2012-08-13 | ||||
| 2011-12-31 | $0.14 10-K · filed 2013-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |